Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease

Breakdown of the neurovascular unit in early Alzheimer’s disease (AD) leads to leakiness of the blood-brain barrier (BBB), contributing to cognitive decline and disease pathology. Vascular stability depends on angiopoietin-1 (ANGPT1) signalling, antagonised by angiopoietin-2 (ANGPT2) upon endothelial injury. We have examined the relationship between CSF ANGPT2 and CSF markers of BBB leakiness and disease pathology, across three independent cohorts: (i) 31 AD patients and 33 healthy controls grouped according to their biomarker profile (i.e., AD cases t-tau > 400 pg/mL, p-tau > 60 pg/mL and Aβ42 < 550 pg/mL); (ii) 121 participants in the Wisconsin Registry for Alzheimer’s Prevention or Wisconsin Alzheimer’s Disease Research study (84 participants cognitively unimpaired (CU) enriched for a parental history of AD, 19 participants with mild cognitive impairment (MCI), and 21 with AD); (iii) a neurologically normal cohort aged 23–78 years with paired CSF and serum samples. CSF ANGPT2 level was measured by sandwich ELISA. In cohort (i), CSF ANGPT2 was elevated in AD, correlating with CSF t-tau and p-tau181 but not Aβ42. ANGPT2 also correlated positively with CSF sPDGFRβ and fibrinogen – markers of pericyte injury and BBB leakiness. In cohort (ii), CSF ANGPT2 was highest in MCI. CSF ANGT2 correlated with CSF albumin in the CU and MCI cohorts but not in AD. ANGPT2 also correlated with t-tau and p-tau and with markers of neuronal injury (neurogranin and α-synuclein) and neuroinflammation (GFAP and YKL-40). In cohort (iii), CSF ANGPT2 correlated strongly with the CSF:serum albumin ratio. Increased CSF ANGPT2 and the CSF:serum albumin ratio showed non-significant associations with elevated serum ANGPT2 in this small cohort. Together, these data indicate that CSF ANGPT2 is associated with BBB leakiness in early AD and is closely related to tau pathology and neuronal injury. The utility of serum ANGPT2 as a biomarker of BBB damage in AD requires further study.

[1]  F. Gao,et al.  Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer’s disease with or without small cerebrovascular lesions , 2023, Alzheimer's Research & Therapy.

[2]  A. Sheikh,et al.  Alzheimer’s Amyloid β Peptide Induces Angiogenesis in an Alzheimer’s Disease Model Mouse through Placental Growth Factor and Angiopoietin 2 Expressions , 2023, International journal of molecular sciences.

[3]  V. Kakkassery,et al.  Increased Angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy , 2023, PloS one.

[4]  F. Sun,et al.  Neuroprotective Effect of Angiopoietin2 Is Associated with Angiogenesis in Mouse Brain Following Ischemic Stroke , 2022, Brain sciences.

[5]  M. Chopp,et al.  Treatment With an Angiopoietin-1 Mimetic Peptide Improves Cognitive Outcome in Rats With Vascular Dementia , 2022, Frontiers in Cellular Neuroscience.

[6]  Jun Wang,et al.  Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers , 2022, Molecular Neurodegeneration.

[7]  M. Chopp,et al.  Treatment with an Angiopoietin‐1 mimetic peptide promotes neurological recovery after stroke in diabetic rats , 2020, CNS neuroscience & therapeutics.

[8]  R. Morishita,et al.  Insight into the Role of Angiopoietins in Ageing-Associated Diseases , 2020, Cells.

[9]  A. Toga,et al.  Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid , 2020, The Journal of Neuroscience.

[10]  Wei Jia,et al.  Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment , 2020, Translational Psychiatry.

[11]  Platelet-Derived Growth Factor Receptor Beta , 2020, Definitions.

[12]  P. Cortelli,et al.  CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia , 2019, Alzheimer's Research & Therapy.

[13]  K. Blennow,et al.  CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology , 2019, Alzheimer's Research & Therapy.

[14]  C. Wykoff,et al.  Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. , 2019, Ophthalmology.

[15]  M. S. Sajib,et al.  Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology , 2019, Cells.

[16]  J. Trojanowski,et al.  Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology , 2019, Molecular Neurodegeneration.

[17]  A. Fagan,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[18]  K. Blennow,et al.  CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease , 2018, Neurology.

[19]  Elin Byman,et al.  Amyloid‐beta 1‐40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro , 2018, Aging cell.

[20]  Berislav V. Zlokovic,et al.  Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.

[21]  I. Ferrer,et al.  YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias , 2017, Molecular Neurodegeneration.

[22]  S. Love,et al.  Differing associations between Aβ accumulation, hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  K. Plate,et al.  Angiopoietin-2-induced blood–brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling , 2016, Acta Neuropathologica.

[24]  Nick C Fox,et al.  Increased CSF neurogranin concentration is specific to Alzheimer disease , 2016, Neurology.

[25]  Seth Love,et al.  Cerebrovascular disease in ageing and Alzheimer’s disease , 2015, Acta Neuropathologica.

[26]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[27]  C. Laske,et al.  Elevated Angiopoietin-1 Serum Levels in Patients with Alzheimer's Disease , 2012, International journal of Alzheimer's disease.

[28]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[29]  D. Stewart,et al.  Increased angiopoietin2 expression is associated with endothelial apoptosis and blood–brain barrier breakdown , 2005, Laboratory Investigation.

[30]  H. Hammes,et al.  Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. , 2004, Diabetes.

[31]  J. LaManna,et al.  Angiopoietin-2 and rat brain capillary remodeling during adaptation and deadaptation to prolonged mild hypoxia. , 2002, Journal of applied physiology.

[32]  S. Mandriota,et al.  Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. , 2000, The American journal of pathology.

[33]  T. Bayer,et al.  Endothelial LRP 1 transports amyloid-β 1 – 42 across the blood-brain barrier , 2015 .

[34]  P. Grammas,et al.  Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.